Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for Cartesian Therapeutics (RNAC) over the last 10 years, with Q1 2024 value amounting to $412000.0.

  • Cartesian Therapeutics' Current Deferred Revenue fell 9577.48% to $412000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $412000.0, marking a year-over-year decrease of 9577.48%. This contributed to the annual value of $5.8 million for FY2023, which is 88634.06% up from last year.
  • Cartesian Therapeutics' Current Deferred Revenue amounted to $412000.0 in Q1 2024, which was down 9577.48% from $5.8 million recorded in Q4 2023.
  • Cartesian Therapeutics' Current Deferred Revenue's 5-year high stood at $115.8 million during Q3 2020, with a 5-year trough of $412000.0 in Q1 2024.
  • Its 5-year average for Current Deferred Revenue is $42.4 million, with a median of $18.3 million in 2020.
  • Per our database at Business Quant, Cartesian Therapeutics' Current Deferred Revenue crashed by 9909.19% in 2022 and then skyrocketed by 88634.06% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Current Deferred Revenue stood at $110.8 million in 2020, then crashed by 41.06% to $65.3 million in 2021, then plummeted by 99.09% to $593000.0 in 2022, then soared by 886.34% to $5.8 million in 2023, then plummeted by 92.96% to $412000.0 in 2024.
  • Its Current Deferred Revenue was $412000.0 in Q1 2024, compared to $5.8 million in Q4 2023 and $8.1 million in Q3 2023.